Clinical trials: Hormone Therapy
Critical Illness, Multi Organ Failure
Parathyroid Hormone Kinetics During CRRT
The objective of this study is to assess the parathyroid hormone serum concentrations and kinetics in critically ill patients admitted to the intensive care unit due to multi-organ failure and undergoing citrate anticoagulation…
- Conditions
- Critical Illness, Multi Organ Failure, Renal Failure, Circulatory Failure
- Trial name
- NCT03873675
- Testing
- parathyroid hormone
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Uniwersytecki Szpital Kliniczny w Opolu
Dose Escalation, Safety
Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies.
- Conditions
- Dose Escalation, Safety, Preliminary Efficacy, Advanced Solid Tumors
- Trial name
- NCT01576666
- Testing
- LDE225, BKM120
- Where
- 23 sites in United States, Australia and 6 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer Metastatic
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
The primary objective is to determine the safety and activity of combined hormonal chemoimmunotherapy in a single-arm phase II trial of REGN2810, androgen deprivation therapy (ADT), and docetaxel in patients with newly…
- Trial name
- NCT03951831
- Testing
- REGN2810, Degarelix, Leuprolide Acetate
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Mark Stein
Premenstrual Dysphoric Disorder
Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)
The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo…
- Trial name
- PMDD (NCT00927095)
- Testing
- Continuous OC (EE/DROS), Intermittent OC (EE/DROS)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- University of North Carolina, Chapel Hill
Breast Cancer, Insomnia
Treatment of Insomnia in Patients With Breast Cancer
Insomnia, defined as difficulty falling asleep, staying asleep, or waking up too early at least three times a week for at least 3 months, (American Psychiatric Association 2013) is a common disorder both in the general population…
- Trial name
- NCT06061666
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Breast Cancer
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
This prospective study recruits patients with ER+/HER2-, non-metastatic breast cancer who omit upfront surgery in favor of primary endocrine therapy for sample collection and prospective circulating tumor DNA (ctDNA) measurement…
- Trial name
- NCT05914792
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Pittsburgh
Osteoporosis
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
This 2-year study will test the effectiveness of combining parathyroid hormone (PTH) and alendronate for treating osteoporosis in postmenopausal women.
- Trial name
- NCT00005005
- Testing
- PTH, Alendronate
- Where
- 4 sites in United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Dennis Black
Postmenopause
Endometrial Safety Study
The study is designed to investigate the safety of the investigational product for the lining of the uterus (endometrium).
- Trial name
- NCT00522873
- Testing
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 662 people
- Sponsor
- Bayer
Down Syndrome
Efficacy Assessment of Systematic Treatment With Folinic Acid and Thyroid Hormone on Psychomotor Development of Down Syndrome Young Children
Evaluation of the following in very young children with Down syndrome: the efficacy of systematic treatment with L-thyroxine at controlled doses (clinically and by ultrasensitive thyreostimulating hormone (TSH) assay), the…
- Trial name
- ACTHYF (NCT01576705)
- Testing
- thyroid hormone and folinic acid
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Institut Jerome Lejeune
Prostate Cancer
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body.
- Trial name
- SHIP0804 (NCT00664456)
- Testing
- Adjuvant therapy, Neoadjuvant therapy, Brachytherapy（iodine I 125）
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Deep Infiltrating Endometriosis (DIE), Infertility
Ultra-Long GnRH-a Pretreatment for FET Outcomes in Patients With Deep Infiltrating Endometriosis
Deep infiltrating endometriosis is a severe form of endometriosis that may reduce fertility and negatively affect pregnancy outcomes after assisted reproductive treatment.
- Trial name
- DIE-GnRHa-FET (NCT07696351)
- Testing
- Triptorelin (GnRH agonists), Hormone Replacement Therapy (HRT)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Li-jun Ding
Idiopathic Short Stature
A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)
This is an open-label, multi-center, randomized, two-arm parallel, no-treatment group controlled (only for the first 6 months), Phase 3 study in children with ISS.
- Trial name
- NCT01746862
- Testing
- Saizen®
- Where
- South Korea
- Volunteers
- 90 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer, Hormone-resistant Prostate Cancer
Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer
This randomized phase II trial studies how well a controlled low calorie diet works in reducing side effects and increasing response to chemotherapy in patients with breast or prostate cancer.
- Conditions
- Breast Cancer, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT01802346
- Testing
- dietary intervention, nutritional support, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- University of Southern California
Breast Cancer, Estrogen Receptor Positive Tumor
To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH)
This is a phase II open-label, multicentre, randomized trial. The study assesses the treatment of postmenopausal patients with hormone receptor positive/HER2 positive early breast cancer with neoadjuvant palbociclib in…
- Conditions
- Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
- Trial name
- TOUCH (NCT03644186)
- Testing
- Paclitaxel, Trastuzumab, Pertuzumab
- Where
- 54 sites in Belgium, France and 2 more
- Volunteers
- 147 people
- Sponsor
- ETOP IBCSG Partners Foundation
Prostate Cancer
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease.
- Trial name
- NCT07237269
- Testing
- Androgen Deprivation Therapy (ADT), Abiraterone, Prednisone
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- University of Nebraska
Infertility
Predictive Value of AMH in IVF; a Prospective RCT
The primary aim of this trial is to compare two groups of women undergoing IVF (IVF=in vitro fertilisation ) treatment, to investigate if assessment of AMH (AMH=Anti-Müllerian hormone ), in addition to assessment of maternal age…
- Trial name
- AMH (NCT02013973)
- Testing
- AMH-analysis
- Where
- Sweden
- Volunteers
- 308 people
- Sponsor
- Ann Thurin Kjellberg
Adrenal Insufficiency
Adherence in Chronic Adrenal Insufficiency
Adherence, concerns and satisfaction with information in German patients with adrenal insufficiency as well as the influence of a standardized education program will be assessed by a compared cross-sectional and longitudinal…
- Trial name
- NCT03399383
- Testing
- Patient education
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Wuerzburg University Hospital
Breast Cancer
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
This study is exploring the safety/tolerabtility and preliminary efficacy of the combination of Ipatasertib with Aromatase inhibitor or Fulvestrant for patients with metastatic HR+ breast cancer.
- Trial name
- NCT03959891
- Testing
- Ipatasertib, Fulvestrant, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Massachusetts General Hospital
Breast Cancer
Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer
The 2014-2019 cancer plan emphasizes the need to "reduce the impact of cancer on personal life". The impact of cancer on sexuality is multifactorial: fatigue, anxiety, impaired body image, chemotherapy treatment.
- Trial name
- NCT03395327
- Testing
- quality of life questionnaire
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Departemental Vendee
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT07288359
- Testing
- GVV858, Fulvestrant, Letrozole
- Where
- 16 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals